- 08 May 2025 10:48:41
- Source: Sharecast
S&P upgrades Hikma Pharmaceuticals PLC and its Senior Notes to 'BBB' on continued good business momentum; outlook stable
London, 8 May 2025 - S&P has today announced that it has raised its long-term issuer credit rating on Hikma Pharmaceuticals PLC (Hikma, Company) and its $500 million notes outstanding due July 9, 2025, issued out of Hikma Finance USA LLC, to 'BBB' from 'BBB-' with a stable outlook. S&P said its rating action reflects Hikma's good business momentum and ability to maintain healthy growth prospects and stable credit metrics.
Khalid Nabilsi, CFO of Hikma said: "I am pleased that S&P have upgraded Hikma today, strengthening our investment grade rating and confirming our solid market position as well as our track record of profitability and cash generation."
-- ENDS --
Enquiries:
Hikma (Investors)
|
Susan Ringdal EVP, Strategic Planning and Global Affairs |
+44 (0)20 7399 2760/ +44 (0)7776 477050 |
|
Guy Featherstone Director, Investor Relations |
+44 (0)20 3892 4389/ +44 (0)7795 896738 |
|
Layan Kalisse Senior Associate, Investor Relations |
+44 (0)20 7399 2788/ +44 (0)7970 709912 |
|
FTI Consulting (Media) Ciara Martin |
+44 (0)7779 775979 |
About Hikma
Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75) (rated BBB/stable S&P and BBB-/positive Fitch)
Hikma helps put better health within reach every day for millions of people around the world. For more than 45 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across North America, the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 9,500 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com
©2025 Hikma Pharmaceuticals PLC. All rights reserved.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
